Research

A new article in Diagnostics by Smudla, Schöchl, Andreas Calatzis and colleagues asks an important question in viscoelastic testing: Is “physiological lysis” really plasmin-mediated fibrinolysis? Using the ClotPro system, with APIRO Diagnostics Kft. assays and consumables, the authors compared a tissue factor-activated EX-assay with an AP-assay containing tranexamic acid to inhibit fibrinolysis in 120 healthy adults. The key finding: low maximum lysis values were essentially

A recent single-centre randomised feasibility trial explored ClotPro-guided, low-dose, prolonged systemic thrombolysis for high- and intermediate-high-risk acute pulmonary embolism patients in the ICU. Instead of giving every patient the standard 100 mg rtPA over 2 hours, the viscoelastometry-guided group received an individualised infusion adjusted according to real-time coagulation and fibrinolysis results, alongside repeated echocardiography to monitor right ventricular re

The Challenge For patients presenting with acute ischaemic stroke, time is brain. The decision to administer thrombolysis must be made within a narrow window — and for patients taking direct oral anticoagulants (DOACs), that decision has historically been complicated by one critical question: how much anticoagulant is on board right now? Standard laboratory DOAC plasma testing takes 45–60 minutes — often too slow to inform a timely thrombolysis decision. As a result, many cl